Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group
Edmonds, Kim, Hull, Diana, Spencer-Shaw, Andrea, Koldenhof, José, Chrysou, Maria, Boers-Doets, Christine, Molassiotis, Alexander
Published in European journal of oncology nursing : the official journal of European Oncology Nursing Society (01.04.2012)
Published in European journal of oncology nursing : the official journal of European Oncology Nursing Society (01.04.2012)
Get full text
Journal Article
High dose Interleukin2 (HD IL2) in metastatic renal cell carcinoma (mRCC) after prior therapy: A single centre experience
Chow, Shien, Leach, Rebecca, Spencer-Shaw, Andrea, Shaheen, Fadhel, Thistlethwaite, Fiona C., Hawkins, Robert E.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC)
Chow, Shien, Pillai, Manon Rhys, Galvis, Victoria, Leach, Rebecca, Keene, Elizabeth, Chan, Kevin, Spencer-Shaw, Andrea, Thistlethwaithe, Fiona, Hawkins, Robert E.
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
High dose Interleukin 2 (HD IL2) as 1 st line treatment in metastatic renal cell carcinoma (mRCC): A 10-year single centre experience
Chow, Shien, Galvis, Victoria, Pillai, Manon, Leach, Rebecca, Keene, Elizabeth, Spencer-Shaw, Andrea, Tom, Liptrot, Shanks, Jonathan, Shablak, Alaaeldin, Thistlethwaithe, Fiona, Hawkins, Robert E.
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer
Shablak, Alaaeldin, Sikand, Kanwal, Shanks, Jonathan H, Thistlethwaite, Fiona, Spencer-Shaw, Andrea, Hawkins, Robert E
Published in Journal of immunotherapy (1997) (01.01.2011)
Published in Journal of immunotherapy (1997) (01.01.2011)
Get more information
Journal Article
Managing adverse events associated with sorafenib in renal cell carcinoma
Edmonds, Kim, Spencer-Shaw, Andrea
Published in British journal of nursing (Mark Allen Publishing) (14.01.2010)
Published in British journal of nursing (Mark Allen Publishing) (14.01.2010)
Get more information
Journal Article
High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
Chow, Shien, Evans, Manon, Galvis, Victoria, Leach, Rebecca, Keene, Elizabeth, Chan, Kevin, Spencer-Shaw, Andrea, Jonathan, Shanks, Shabalak, Alaaeldin, Thistlethwaite, Fiona, Hawkins, Robert
Published in Journal for immunotherapy of cancer (06.11.2014)
Published in Journal for immunotherapy of cancer (06.11.2014)
Get full text
Journal Article